On February 22, Guangdong Medical Products Administration (Guangdong MPA) announced ten measures to support drug, medical device and cosmetic enterprises to resume operations amid the COVID-19 outbreak. The emphasis of the policy revolves in the administrative service time extension, review and approval procedures optimization, inspection and verification process simplification as well as registration fee exemption.
The policy's implementation period is tentatively scheduled for three months. Any measures with a clearly defined execution time shall be implemented within the prescribed period.
CONTINUE READING ON cosmetic.chemlinked.com